Systemic exposure to butenafine is low after topical administration of Mentax®

Journal of Dermatological Treatment

Volumn 8, Issue 4, 1997, Pages 237-241

  Gibbs, L ^a   Alonzo, G ^a   Bon, C ^b   Brennan, B ^a   Calvarese, B ^a   Chaudhuri, B ^a   Chavdarian, C ^a   Wagner, G ^a  

^a Penederm Inc   (United States)

^b Novum Inc   (United States)

Author keywords

Butenafine; Mentax

Indexed keywords

BUTENAFINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CREAM; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; DRUG URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

EID: 0031466868     PISSN: 09546634     EISSN: None     Source Type: Journal    
DOI: 10.3109/09546639709160528     Document Type: Article

References (4)

1. Maeda T et al, Synthesis and antifungal activity of butenafine hydrochloride (KP-363), a new benzylamine antifungal agent Yakugaku Zasshi (1991) 111(2): 126-37.
2. Winer BJ, Statistical principles in experimental design. McGraw-Hill Book Company: New York, 1962, pp 21-6.
3. Dykes PJ, Thomas R, Lever L, Marks R, Pharmacokinetics of topically applied terbinafine: results from studies in healthy volunteer subjects and patients with pityriasis versicolor. J Dermatol Treat (1990) 1(suppl 2): 19-21.
4. Guy RH, Maibach HI, Calculations of body exposure from percutaneous absorption data. In: Bronaugh RL, Mailbach HI, (eds), Percutaneous absorption: mechanisms-methodology-drug delivery. Marcel Dekker: New York, 1989, pp 391-6.